Viral Vitalism

Medicine

Sickle Cell Disease

Sickle Cell Disease news, research, studies, and rapid health briefings. Visit Viral Vitalism for plain-language context, evidence boundaries, and related signals.

0 published articles5 rapid briefs
Coverage is being assembled with research and source context before this hub is promoted publicly.

News cycle

Rapid Briefs

View all ->
Gene TherapyConfirmed

FDA Expanded CRISPR Therapy to Children as Young as 2

Casgevy's label expansion moves CRISPR-based treatment access earlier for some children with sickle cell disease or transfusion-dependent beta thalassemia, but the treatment remains intensive and transplant-like.

Why now

The age expansion moves CRISPR medicine from teens and adults into much younger children for two severe inherited blood disorders.

Overclaim risk
high
Primary source
Official
Published
Jul 5, 2026
Gene EditingReported

CRISPR Therapy Shows Early Promise in Children Ages 5 to 11 With Blood Disorders

NEJM published first pediatric data for exa-cel in children under 12 with sickle cell disease or transfusion-dependent beta thalassemia.

Why now

CRISPR medicine is moving younger, raising the early-intervention question before years of organ damage accumulate.

Overclaim risk
high
Primary source
Primary
Published
Jun 30, 2026
Gene TherapyReported

McKenzie Is Preparing to Become CHLA's First Casgevy Patient

A young actress and Spelman graduate is preparing for Casgevy after years of sickle-cell pain crises, but her treatment story is still pre-infusion.

Why now

McKenzie's story lets VV track a Casgevy journey from collection and manufacturing through infusion, rather than only covering the post-treatment headline.

Overclaim risk
medium-high
Primary source
Official
Published
Jun 27, 2026
Gene TherapyDeveloping

Columbia Says Newer Gene Therapies Could Give Sickle Cell Patients More Options

Two NEJM-published experimental approaches show the sickle-cell gene therapy field moving from one breakthrough toward multiple strategies.

Why now

Columbia's update helps shift the sickle-cell gene therapy narrative from a single approved breakthrough to an emerging field of distinct strategies, risks, and access tradeoffs.

Overclaim risk
medium-high
Primary source
Trade news
Published
Jun 27, 2026
Good News MedicineConfirmed

A 23-Year-Old in Louisiana Was Functionally Cured of Sickle Cell Disease

Sickle cell disease blocked Daniel Cressy's path to becoming a commercial pilot. After Casgevy gene therapy, the 23-year-old is working toward that future again.

Why now

A patient-level milestone is moving gene therapy from approval news into real-world care in Louisiana and national coverage.

Overclaim risk
medium
Primary source
Official
Published
Jun 24, 2026

Research map

View related studies

Research records connected to this topic through topic tags, source records, and timeline events.

No directly linked studies are available for this page yet. Topic-only matches are not shown as evidence.

Useful source library entries

Related topics

Vital Signals

Get the weekly health signal without the wellness fog.

A clean weekly brief covering longevity science, fitness, nutrition, medicine, health culture, and the claims worth questioning.

No spam. No selling your information. Unsubscribe anytime.

By subscribing, you agree to receive email from Viral Vitalism. Unsubscribe anytime. See our Privacy Policy.